Enterprise Value
44.3M
Cash
127.5M
Avg Qtr Burn
-40.1M
Short % of Float
25.71%
Insider Ownership
31.03%
Institutional Own.
60.64%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BXCL501 Details Bipolar depression, Bipolar disease, Mental health, Schizophrenia | Approved Quarterly sales | |
BXCL501 Details Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease | sNDA Submission | |
BXCL501 Details Bipolar depression, Bipolar disease, Mental health, Schizophrenia | Phase 3 Update | |
BXCL701 + KEYTRUDA Details Neuroendocrine prostate cancer, Castration-resistant prostate cancer | Phase 2b Initiation | |
BXCL701 + KEYTRUDA Details Solid tumor/s, Pancreatic cancer, Cancer | Phase 2 Data readout | |
BXCL501 + Duloxetine Details Major depressive disorder | Phase 2 Initiation | |
BXCL501 Details Mental health, Delirium, Agitation | Failed Discontinued | |
BXCL501 Details Opioid use disorder | Failed Discontinued |